compound of Formula (VI) wherein R_{14} and R_{15} are each H. In another embodiment is a compound of Formula (VI) wherein R_{21} is -OH, $-N(R_{22})S(=O)_2R_{23}$, $-CO_2R_{22}$, $-C(=O)N(R_{22})_2$, $-N(R_{22})C(=O)R_{23}$, substituted or unsubstituted C_1-C_6alkoxy, or substituted or unsubstituted C_2-C_7heteroaryl. In another embodiment of the aforementioned embodiments, is a compound of Formula (VI) wherein R_{21} is -OH. In another embodiment of the aforementioned embodiments, is a compound of Formula (VI) wherein R_{21} is $-N(R_{22})S(=O)_2R_{23}$. In another embodiment of the aforementioned embodiments, is a compound of Formula (VI) wherein R_{21} is $-N(R_{22})C(=O)R_{23}$. In a further embodiment, R_{21} is $-N(R_{22})S(=O)_2R_{23}$. In another embodiment of the aforementioned embodiments, is a compound of Formula (VI) wherein R_{21} is substituted or unsubstituted C_1-C_6alkoxy. In another embodiment of the aforementioned embodiments, is a compound of Formula (VI) wherein R_{21} is substituted or unsubstituted C_2-C_7heteroaryl. In another embodiment is a compound of Formula (VI) wherein each R_{22} is independently H or unsubstituted C_1-C_6alkyl; and R_{23} is unsubstituted C_1-C_6alkyl. In another embodiment is a compound of Formula (VI) wherein m is 2. In another embodiment is a compound of Formula (VI) wherein m is 3. In another embodiment is a compound of Formula (VI) wherein R_6 is



. In another embodiment is a compound of Formula (VI) wherein R_6 is



. In another embodiment is a compound of Formula (VI) wherein R_{13} is H or unsubstituted C_1-C_6alkyl. In another embodiment is a compound of Formula (VI) wherein each R_1 is independently halogen, $-OCF_3$, $-CF_3$, unsubstituted C_1-C_6alkyl, or unsubstituted C_1-C_6alkoxy. In another embodiment is a compound of Formula (VI) wherein each R_1 is independently halogen. In another embodiment is a compound of Formula (VI) wherein n is 1. In another embodiment is a compound of Formula (VI) wherein each R_1 is independently halogen. In another embodiment is a compound of Formula (VI) wherein n is 2. In another embodiment is a compound of Formula (VI) wherein each R_1 is independently halogen. In another embodiment is a compound of Formula (VI) wherein n is 0.

[0011a] In another aspect, there is provided a compound having a structure selected from:


,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

, and

; or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

[0012] In another aspect is a pharmaceutical composition comprising a compound of Formula (I), (II), or (IIA) or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and at least one pharmaceutically acceptable excipient. In another aspect is a pharmaceutical composition comprising a compound of Formula (I), (II), (IIA), or (VI) or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and at least one pharmaceutically acceptable excipient.

[0012a] In another aspect, there is provided use of a composition comprising a compound as described herein, or a pharmaceutically acceptable salt, solvate, or prodrug thereof; in the manufacture of a medicament for treating a disease in a subject wherein the disease is cancer or Down's Syndrome.

[0012b] In another aspect, there is provided use of a compound as described herein, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, in the manufacture of a medicament for inhibiting the activity of Olig2 in a cell.


,

,

,

,

,

,

,

,

,

,

,

, and

; or a pharmaceutically acceptable salt, solvate, or prodrug thereof.

111. A pharmaceutical composition comprising a compound of any one of claims 1-110, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and at least one pharmaceutically acceptable excipient.

112. Use of a composition comprising a compound of any one of claims 1-110, or a pharmaceutically acceptable salt, solvate, or prodrug thereof; in the manufacture of a medicament for treating a disease in a subject wherein the disease is cancer or Down's Syndrome.

113. The use of claim 112, wherein the disease is cancer.

114. The use of claim 113, wherein the cancer is brain cancer, glioblastoma multiforme, medulloblastoma, astrocytomas, brain stem gliomas, meningiomas, oligodendrogliomas, melanoma, lung cancer, breast cancer, or leukemia.

115. The use of claim 112, wherein the disease is Down's Syndrome.

116. Use of a compound of any one of claims 1-110, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, in the manufacture of a medicament for inhibiting the activity of Olig2 in a cell.